<DOC>
	<DOC>NCT01956825</DOC>
	<brief_summary>The purpose of this study is to determine whether the dual therapy of the amino acid L-CARNITINE and magnesium have an effect on reducing the liver fat content in patients with non alcoholic fatty liver disease (NAFLD).</brief_summary>
	<brief_title>The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver</brief_title>
	<detailed_description>The purpose of this study is to determine whether the dual therapy of the amino acid L-CARNITINE and magnesium have an effect on reducing the liver fat content in patients with non alcoholic fatty liver disease. the study is an interventional one in which 60 patients who by definition have non alcoholic fatty licer disease (NAFLD) are divided randomly (double blind) into 2 groups: group 1: "study group". receive a product (flavoured water) which contains L-CARNITINE an magnesium. group 2: control. receive placebo. regular water. Length of trial - 12 weeks. The patients will be followed on a weekly base and variuos parameters will be compared (weight, lipid profile, insulin resistance etc.). "fibrotest" will be used at the beginning of the trial and at the end (week 12) comparing the fat content before and after the treatment.</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>age&gt;18, &lt;80 y evidence to non alcoholic fatty liver disease age&lt;18, &gt;80 y pregnancy renal failure congestive heart failure active malignancy liver disease etiology other than non alcoholic fatty liver disease (NAFLD). hypothyroidism/cushing total prenteral nutrition (TPN) in the last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>non alcoholic fatty liver disease</keyword>
	<keyword>LCARNITINE amino acid</keyword>
	<keyword>magnesium</keyword>
	<keyword>fat content</keyword>
</DOC>